EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 120

Change

+1.20 (+1.01)%

Market Cap

USD 0.70B

Volume

2.58K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

+0.62 (+1.33%)

USD 96.80B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.24 (+0.23%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.25 (+1.04%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

+0.16 (+1.20%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

+0.07 (+1.24%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

+0.20 (+0.84%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

N/A

USD 23.43B
PPFB:XETRA iShares Physical Gold ETC EUR

+0.30 (+0.55%)

USD 19.49B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

+0.09 (+0.89%)

USD 12.83B
EUN5:XETRA iShares Core Corporate Bond UC..

-0.16 (-0.13%)

USD 12.26B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.91% 87% B+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.91% 87% B+ 82% B
Trailing 12 Months  
Capital Gain 7.09% 41% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.09% 41% F 43% F
Trailing 5 Years  
Capital Gain 32.48% 47% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.48% 47% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain 7.38% 52% F 53% F
Dividend Return 8.42% 55% F 55% F
Total Return 1.04% 70% C- 50% F
Risk Return Profile  
Volatility (Standard Deviation) 7.97% 71% C- 77% C+
Risk Adjusted Return 105.68% 90% A- 91% A-
Market Capitalization 0.70B 78% C+ 59% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike